Ecopipam Priority Review Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)

Teva and Aurinia resolved their patent dispute over the lupus drug voclosporin, allowing Teva to launch its generic version. The agreement ends all litigation between the two companies.

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

Aurinia Pharmaceuticals (AUPH) settled patent litigation with Teva, which agreed to not launch its generic voclosporin product until December 7, 2036, unless certain conditions are met. Teva acknowledged the validity of Aurinia's patents, which expire in December 2037. Aurinia's litigation against other companies continues.

Teva Pharmaceutical (TEVA) announced the FDA accepted its NDA for Ecopipam, a potential treatment for Tourette syndrome in children, and granted priority review. The application is backed by positive Phase 3 results and Phase 2b data. If approved, Ecopipam would be the first new treatment in over a decade. The FDA's targeted action date is Q1 2027. TEVA shares rose 1.59% in pre-market trading.

Teva Pharmaceutical Industries' NDA for Ecopipam, a first-in-class therapy for pediatric Tourette Syndrome, has been accepted and granted Priority Review by the U.S. FDA, according to the company.

Moody’s Ratings upgraded Teva Pharmaceutical Industries (NYSE:TEVA) to investment grade, raising its issuer rating to Baa3 from Ba1 and changing the outlook to stable from positive. Moody’s cited branded sales growth, pipeline expansion, and deleveraging. It expects gross debt/EBITDA to fall below 3.75x, and forecasts about $2.0B free cash flow over 12 months.